Results 31 to 40 of about 1,124 (174)
Retrospective Analysis of Phase 4 Clinical Trial to Evaluate the Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension [PDF]
, 2021 One of the biggest challenges patients with rare diseases face is the availability of safe and effective treatment options. Patients with symptomatic neurogenic orthostatic hypotension have a very limited number of pharmacological treatment options ...
Lombard, Diandra
core +2 more sources
Clinical management of neurogenic orthostatic hypotension
Annals of Movement Disorders, 2019 Neurogenic orthostatic hypotension is a common disorder often seen in elderly patients affected with neurodegenerative disorders and peripheral neuropathies.
Malligurki Raghurama Rukmani +3 more
doaj +1 more source
Clinical Parkinsonism & Related Disorders, 2022 Introduction: Orthostatic hypotension (OH) and abnormal blood pressure (BP) fluctuations occur mainly due to noradrenergic dysfunction and are clinically important in patients with Parkinson’s disease (PD). They lead to impairments of cognition function,
Hisayoshi Oka +3 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background Neurogenic orthostatic hypotension, a sustained decrease in blood pressure upon standing, is caused by autonomic nervous system failure and characterized by an insufficient increase in heart rate needed to maintain blood pressure upon standing.
Sameh K. Mobarek
doaj +1 more source
Frontiers in Neurology, 2023 BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki +4 more
doaj +1 more source
Droxidopa and reduced falls in a trial of Parkinson disease patients with Neurogenic orthostatic hypotension [PDF]
, 2016 Objectives: Droxidopa is a prodrug of norepinephrine indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by ...
Robert A. Hauser +9 more
core +1 more source
Cardiology and Therapy, 2019 Introduction The prevalence of neurogenic orthostatic hypotension (nOH) increases with age and is associated with autonomic failure in neurodegenerative diseases (e.g., Parkinson's disease).
Peter A. McCullough
doaj +1 more source
Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde [PDF]
Clinical Chemistry, 2010 AbstractBackground: l-Threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa) is a norepinephrine (NE) prodrug under development to treat orthostatic hypotension. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an endogenous catecholaldehyde produced by enzymatic oxidative deamination of dopamine, is toxic to catecholaminergic neurons. Based on the observation of
Courtney, Holmes +3 more
openaire +2 more sources
Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
International Journal of General Medicine, 2021 Fahd Amjad,1 Brett Polenchar,2 Antonella Favit3 1Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA; 2Business Insights, Lundbeck, Deerfield, IL, USA; 3Medical Affairs, Lundbeck, Deerfield, IL ...
Amjad F, Polenchar B, Favit A
doaj
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2015 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Amanda J, Ross, Julian M, Stewart
openaire +2 more sources